# US 2021/0196705 A1 · Bupropion as a modulator of drug activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196705 A1
- Document ID: US20210196705A1
- Status: Published application
- Kind: A1
- Application number: 17/199,112
- Filed: 2021-03-11
- Published: 2021-07-01
- Earliest claimed: 2013-11-05
- Assignees: Antecip Bioventures II LLC
- Applicants: Antecip Bioventures II LLC
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20210196705A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/381: having five-membered rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

## Claims

### Claim 1

A method of increasing dextromethorphan plasma levels, comprising co-administering bupropion and dextromethorphan once a day or twice a day for at least 8 consecutive days to a human being who is a non-poor metabolizer of dextromethorphan in need of treatment with dextromethorphan; wherein about 50 mg to about 220 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 40 mg to about 60 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, once a day or twice a day; and wherein co-administering the bupropion and the dextromethorphan results in an AUC0-24 of dextromethorphan on the eighth day that is about 20 times to about 1,000 times the AUC0-24 that would result from administering 60 mg of dextromethorphan hydrobromide without bupropion for eight consecutive days.

### Claim 2 (depends on 1)

The method of claim 1, wherein co-administering the bupropion and the dextromethorphan results in an AUC0-24 of dextromethorphan on the eighth day that is about 20 times to about 80 times the AUC0-24 that would result from administering 60 mg of dextromethorphan hydrobromide without the bupropion for eight consecutive days.

### Claim 3 (depends on 2)

The method of claim 2, wherein about 70 mg to about 150 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 40 mg to about 60 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, once a day or twice a day.

### Claim 4 (depends on 3)

The method of claim 3, wherein the AUC0-24 of dextromethorphan on the eighth day is about 1,900 ng·hr/mL.

### Claim 5 (depends on 3)

The method of claim 3, wherein the AUC0-24 of dextromethorphan on the eighth day is about 1,300 ng·hr/mL to 2,975 ng·hr/mL.

### Claim 6 (depends on 5)

The method of claim 5, wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 44 mg to about 46 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan, once a day or twice a day.

### Claim 7 (depends on 5)

The method of claim 5, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression.

### Claim 8 (depends on 5)

The method of claim 5, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction.

### Claim 9 (depends on 5)

The method of claim 5, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease.

### Claim 10 (depends on 5)

The method of claim 5, wherein the Cmax of dextromethorphan on the eighth day is about 75 mg/mL to 158 mg/mL.

### Claim 11 (depends on 10)

The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression.

### Claim 12 (depends on 10)

The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction.

### Claim 13 (depends on 10)

The method of claim 10, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease.

### Claim 14 (depends on 10)

The method of claim 10, wherein the Cmin of dextromethorphan on the eighth day is about 50 mg/mL to 119 mg/mL.

### Claim 15 (depends on 14)

The method of claim 14, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression.

### Claim 16 (depends on 14)

The method of claim 14, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of nicotine addiction.

### Claim 17 (depends on 14)

The method of claim 14, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of agitation associated with Alzheimer's disease.

### Claim 18 (depends on 14)

The method of claim 14, wherein the bupropion and dextromethorphan are co-administered once a day or twice a day for at least 14 consecutive days.

### Claim 19 (depends on 14)

The method of claim 14, wherein the bupropion and dextromethorphan are co-administered once a day or twice a day for at least 30 consecutive days.

### Claim 20 (depends on 14)

The method of claim 14, wherein the human being is converted to poor metabolizer status on the eighth day after co-administering the bupropion and the dextromethorphan.
